Tema ETFs LLC Purchases Shares of 10,170 Inhibrx Biosciences, Inc. $INBX

Tema ETFs LLC purchased a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX) during the 2nd quarter, HoldingsChannel reports. The firm purchased 10,170 shares of the company’s stock, valued at approximately $964,000.

Several other large investors have also made changes to their positions in the business. Persistent Asset Partners Ltd bought a new stake in Inhibrx Biosciences during the 4th quarter valued at approximately $27,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Inhibrx Biosciences by 26.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after purchasing an additional 147 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Inhibrx Biosciences during the fourth quarter worth about $66,000. Public Employees Retirement System of Ohio acquired a new stake in Inhibrx Biosciences during the third quarter worth about $40,000. Finally, Diadema Partners LP bought a new position in Inhibrx Biosciences during the fourth quarter valued at about $103,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Wall Street Zen upgraded Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 9th. Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $150.00.

Inhibrx Biosciences Trading Down 1.4%

Shares of INBX stock opened at $97.01 on Friday. The company has a market capitalization of $1.42 billion, a P/E ratio of -11.56 and a beta of 3.51. The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. Inhibrx Biosciences, Inc. has a 12-month low of $22.40 and a 12-month high of $155.29. The firm has a 50-day moving average price of $90.85 and a 200 day moving average price of $88.48.

Inhibrx Biosciences (NASDAQ:INBX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). Research analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 earnings per share for the current fiscal year.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.